Nov 8, 2018 by Brian Orelli, PhDNovo Nordisk Continues Its Balancing ActGrowth on one hand, but declines on the other.
Nov 7, 2018 by Brian Orelli, PhDHere's Why ImmunoGen Closed Almost 12% Up on WednesdayAn insider buy piques investors' interest.
Nov 7, 2018 by Brian Orelli, PhDHere's Why Alnylam Pharmaceuticals Crashed 11.9% on WednesdayInvestors were expecting a faster launch for the biotech's new drug, Onpattro.
Nov 7, 2018 by Brian Orelli, PhDHere's Why Diplomat Pharmacy Plummeted TodayThe specialty pharmacy is having trouble justifying its pharmacy benefit manager purchases.
Nov 6, 2018 by Brian Orelli, PhDEmergent BioSolutions Nabs Its Acquisition (Times 2)The bioterrorism-response company expands externally.
Nov 5, 2018 by Brian Orelli, PhDExelixis Grabs Its Share of the Kidney-Cancer Treatment MarketLiver cancer treatment is next on the biotech's checklist.
Nov 5, 2018 by Brian Orelli, PhDIDEXX Lets the 2019 Cat Out of the BagThe animal diagnostic company expects to continue its double-digit growth next year.
Nov 1, 2018 by Brian Orelli, PhDHere's Why bluebird bio Jumped 13.5% TodayEarly data from the American Society of Hematology meeting suggests the biotech's drug pipeline is as strong as ever.
Nov 1, 2018 by Brian Orelli, PhDQIAGEN Acquires GrowthWith lackluster growth, the diagnostic test and lab supplier acquired an option to get into a new diagnostic test market.
Oct 31, 2018 by Brian Orelli, PhDBioMarin Keeps on Pace for Its $2 Billion GoalThe orphan-disease drugmaker continues to register revenue growth.
Oct 30, 2018 by Brian Orelli, PhDHere's Why Veracyte Jumped 22.5% Higher TodayThe genomic test maker posted a mighty fine third quarter.
Oct 30, 2018 by Brian Orelli, PhDSeattle Genetics: "Now the Hard Work Begins"Front-line Hodgkin lymphoma turns out to be a tough market to crack.
Oct 29, 2018 by Brian Orelli, PhDCelgene Beats and Raises, but It's All About the PipelineInvestors look beyond a solid quarter to the drugs in development.
Oct 29, 2018 by Brian Orelli, PhDVertex Pharmaceuticals Waits to Hit the TripleThe biotech's current cystic fibrosis drugs are still growing well.
Oct 26, 2018 by Brian Orelli, PhDHere's Why Seattle Genetics Plummeted TodayThird-quarter earnings weren't what investors (or management) were hoping for.
Oct 25, 2018 by Brian Orelli, PhDNatus Medical Takes Baby Steps ForwardAnother lackluster quarter, but the medical device maker is trying to turn things around.
Oct 24, 2018 by Brian Orelli, PhDHere's Why Tesaro Inc. Dropped 13.8% TodayInvestors continue to digest data from the biotech's competitors.
Oct 24, 2018 by Brian Orelli, PhDBiogen Rides the Spinraza Wave to Double-Digit GrowthUnfortunately this wave will eventually hit the shore and the next wave to catch is still developing way off shore.
Oct 22, 2018 by Brian Orelli, PhDHere's Why Kura Oncology Fell TodayThe biotech's drug works -- just not on as many people as investors would have hoped for.
Oct 22, 2018 by Brian Orelli, PhDHere's Why ImmunoGen Fell TodayData presented at a medical conference weren't as good as investors were hoping for.
